The microbial world has been a rich source of medicines, but our ability to explore the full potential of the microbes both in us and around us has been limited by technology and the difficulty of culturing most microbes in a lab. Biosortia Microbiomics has developed a platform for finding, amplifying, and screening microbes as a potential source of novel, small molecule drugs. We spoke to Ross Youngs, CEO and founder of Biosortia, about the case for exploring various microbiomes to discover new small molecule drugs, how the company’s platform technology enables it to investigate a much broader range of microbes, and its business model for capitalizing on the discoveries it makes.
The Year in Biotech and What’s Ahead in 2021
Bringing Precision Cancer Care to Dogs
As COVID-19 Vaccines Ship, One Company Brings Innovation to the Vials
Advancing an Antibody to Prevent and Treat Cytokine Storms in COVID-19
Using AI Created Digital Twins to Accelerate Clinical Trials
Modulating RNA to Quell Disease
A Quest to Extend Life through Early Disease Detection
Modulating a Gatekeeper of Cellular Metabolism to Treat a Range of Diseases
Finding the Best Cell for the Job
Transforming Clinical Trials with Digital Technology
Designing Immunotherapies that Can Overcome Recurrence and Resistance
Extending Precision Medicine Beyond Cancer
Growing Biologics
An Experimental COVID-19 Vaccine Begins Human Clinical Trials
Speeding the Delivery of CAR-T Therapies While Cutting the Cost
Transforming Infused Biologics into Injectables
A Novel Approach to NASH That May Have Benefits for COVID 19 As Well
Will a Focus on Protein Dysregulation Help Prothena Break from the Fold
After FDA Set Back, AI Driven Drug Company Advances with New CEO
A Gamified Therapy System Helps People with Brain Injury Recover
Create your
podcast in
minutes
It is Free
DNA Today: A Genetics Podcast
Short Wave
Stuff To Blow Your Mind
Unexplainable
All In The Mind